Amphastar Pharmaceuticals, Inc. (AMPH): Price and Financial Metrics

Amphastar Pharmaceuticals, Inc. (AMPH)

Today's Latest Price: $14.25 USD

0.59 (-3.98%)

Updated Apr 1 4:00pm

Add AMPH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AMPH Stock Summary

  • Amphastar Pharmaceuticals Inc's stock had its IPO on June 25, 2014, making it an older stock than just 20.51% of US equities in our set.
  • The price/operating cash flow metric for Amphastar Pharmaceuticals Inc is higher than 78.56% of stocks in our set with a positive cash flow.
  • Over the past twelve months, AMPH has reported earnings growth of -816.6%, putting it ahead of merely 2.06% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Amphastar Pharmaceuticals Inc are CORT, CHRS, EXEL, FORM, and LSCC.
  • Visit AMPH's SEC page to see the company's official filings. To visit the company's web site, go to
AMPH Daily Price Range
AMPH 52-Week Price Range

AMPH Stock Price Chart More Charts

AMPH Price/Volume Stats

Current price $14.25 52-week high $23.06
Prev. close $14.84 52-week low $12.32
Day low $14.06 Volume 234,787
Day high $14.72 Avg. volume 251,659
50-day MA $16.88 Dividend yield N/A
200-day MA $19.20 Market Cap 658.89M

Amphastar Pharmaceuticals, Inc. (AMPH) Company Bio

Amphastar Pharmaceuticals focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company was founded in 1996 and is based in Rancho Cucamonga, California.

AMPH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Amphastar Pharmaceuticals Inc. To summarize, we found that Amphastar Pharmaceuticals Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Amphastar Pharmaceuticals Inc, consider:

  • Its compound free cash flow growth rate, as measured over the past 4.98 years, is -0.18% -- higher than only 10.64% of stocks in our DCF forecasting set.
  • The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than only 18% of the free cash flow producing stocks we're observing.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMPH, try ALC, CSII, ELAN, HAPP, and MEDS.

AMPH Latest News Stream

Event/TimeNews Detail
Loading, please wait...

AMPH Latest Social Stream

Loading social stream, please wait...

View Full AMPH Social Stream

AMPH Price Returns

1-mo -10.09%
3-mo -26.36%
6-mo -27.99%
1-year -33.22%
3-year -1.72%
5-year -4.68%
YTD -26.13%
2019 -3.07%
2018 3.43%
2017 4.45%
2016 29.44%
2015 22.57%

Continue Researching AMPH

Want to see what other sources are saying about Amphastar Pharmaceuticals Inc's financials and stock price? Try the links below:

Amphastar Pharmaceuticals Inc (AMPH) Stock Price | Nasdaq
Amphastar Pharmaceuticals Inc (AMPH) Stock Quote, History and News - Yahoo Finance
Amphastar Pharmaceuticals Inc (AMPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7748 seconds.